These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34707005)

  • 21. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
    Li X; Tan Q; Li H; Yang X
    J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 23. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
    Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
    Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive and Prognostic Value of Tumor- Infiltrating Lymphocytes for Pathological Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
    Mohammed AA; Mostafa Elsayed F; Algazar M; Rashed HE
    Gulf J Oncolog; 2022 Jan; 1(38):53-60. PubMed ID: 35156645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
    Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
    Chen D; Wang Q; Dong M; Chen F; Huang A; Chen C; Lu Y; Zhao W; Wang L
    BMC Cancer; 2023 Oct; 23(1):984. PubMed ID: 37845617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Ma M; Gan L; Liu Y; Jiang Y; Xin L; Liu Y; Qin N; Cheng Y; Liu Q; Xu L; Zhang Y; Wang X; Zhang X; Ye J; Wang X
    Eur J Radiol; 2022 Jan; 146():110095. PubMed ID: 34890936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
    Wu K; Yang Q; Liu Y; Wu A; Yang Z
    World J Surg Oncol; 2014 Apr; 12():95. PubMed ID: 24731479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
    Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
    Singareeka Raghavendra A; Liu D; Shen Y; Barcenas CH; Ueno NT; Giordano S; Tripathy D; Sri Karuturi M
    Breast Cancer Res Treat; 2024 Aug; 207(1):81-90. PubMed ID: 38916821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Kennedy WR; Tricarico C; Gabani P; Weiner AA; Altman MB; Ochoa LL; Thomas MA; Margenthaler JA; Sanati S; Peterson LL; Ma CX; Ademuyiwa FO; Zoberi I
    J Natl Compr Canc Netw; 2020 Mar; 18(3):288-296. PubMed ID: 32135512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast-Conserving Surgery in Triple-Negative Breast Cancer: A Retrospective Cohort Study.
    Zhang H; Wang Z; Liu W; Wang P; Zhang X
    Evid Based Complement Alternat Med; 2023; 2023():5431563. PubMed ID: 36704213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.